Evidence map›Paper›PMID 34646778›Full record

ReviewFrontiers in oncology2021

Application of Organoid Models in Prostate Cancer Research.

Ligui Zhou, Caiqin Zhang, Yongbin Zhang, Changhong Shi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Harnessing Organoid Platforms for Nanoparticle Drug Development.Drug design, development and therapy · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Organoids: opportunities and challenges of cancer therapy.Frontiers in cell and developmental biology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ligui ZhouAnimal Experiment Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Caiqin ZhangDivision of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi'an, China.
Yongbin ZhangAnimal Experiment Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Changhong ShiDivision of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complex heterogeneity is an important characteristic in the development of prostate cancer (PCa), which further leads to the failure of known therapeutic options. PCa research has been hampered by the current

Indexed as

drug screeningheterogeneityindividualized treatmentorganoid modelpathogenesisprostate cancer (PCa)

Identifiers

PMID34646778
PMCPMC8504437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.